We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-29.00 | -1.60% | 1,783.50 | 1,779.50 | 1,780.50 | 1,802.00 | 1,775.50 | 1,792.50 | 5,323,517 | 16:35:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.87 | 73.28B |
By Ian Walker
LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Tuesday it will invest $25 million in a new global fund for dementia research by the U.K. government.
The Dementia Discovery Fund is being established by the U.K. government in partnership with leading pharmaceutical companies and Alzheimer's Research U.K., to address the rising threat posed by dementia by supporting research into future treatments. It has received initial commitments totaling $100 million.
The fund aims to identify and nurture promising new avenues of research from around the world in the field of dementia.
According to the World Health Organization more than 35 million people are living with dementia worldwide. This number is expected to triple by 2050, yet there are currently no medicines available to prevent or cure this disease.
"As well as the $25 million contribution we've announced today, we can bring GSK's neurosciences expertise to this novel venture, which, combined with that of other partners, puts us in a good position to invest in some potentially exciting new therapies," Glaxo's President of Pharmaceutical R&D Patrick Vallance said.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions